Palvella Therapeutics, Inc. Current Income Tax Expense (Benefit)
Palvella Therapeutics, Inc. (PVLA) reported Current Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-31
- Palvella Therapeutics, Inc. current income tax expense (benefit) for the quarter ending 2014-09-30 was $0.00.
- Palvella Therapeutics, Inc. current income tax expense (benefit) for the quarter ending 2014-06-30 was $0.00.
- Palvella Therapeutics, Inc. current income tax expense (benefit) for the quarter ending 2014-03-31 was $0.00.
- Palvella Therapeutics, Inc. current income tax expense (benefit) for the quarter ending 2013-12-31 was $0.00.
- Palvella Therapeutics, Inc. current income tax expense (benefit) for fiscal 2025 was $0.00.
- Palvella Therapeutics, Inc. current income tax expense (benefit) for fiscal 2024 was $0.00.
- Palvella Therapeutics, Inc. current income tax expense (benefit) for fiscal 2023 was $0.00.
- Palvella Therapeutics, Inc. current income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Current Income Tax Expense (Benefit) 1 month | Current Income Tax Expense (Benefit) 3 month | Current Income Tax Expense (Benefit) 6 month | Current Income Tax Expense (Benefit) 9 month | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-31 | |||||
| 2024-12-31 | $0.00 10-K · filed 2026-03-31 | |||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | |||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 | |||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 | |||||
| 2020-12-31 | $164.00K 10-K · filed 2022-03-02 | |||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-31 | |||||
| 2018-12-31 | -$148.00K 10-K · filed 2020-03-13 | |||||
| 2017-12-31 | $1.10M 10-K · filed 2019-03-18 | |||||
| 2016-12-31 | $162.00K 10-K · filed 2018-03-15 | $161.97K 10-K · filed 2017-03-30 | ||||
| 2015-12-31 | $203.87K 10-K · filed 2017-03-30 | |||||
| 2014-12-31 | -$18.00 10-K · filed 2016-03-23 | |||||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-13 | $0.00 derived: sum of 2 quarters · filed 2014-11-13 | $0.00 derived: sum of 3 quarters · filed 2014-11-13 | $0.00 derived: sum of 4 quarters · filed 2014-11-13 | ||
| 2014-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-12 | $0.00 derived: sum of 2 quarters · filed 2014-09-12 | $0.00 derived: sum of 3 quarters · filed 2014-09-12 | $0.00 10-K · filed 2014-09-12 | ||
| 2014-03-31 | $0.00 10-Q · filed 2014-06-02 | $0.00 derived: sum of 2 quarters · filed 2014-06-02 | $0.00 10-Q · filed 2014-06-02 | |||
| 2013-12-31 | $0.00 10-Q · filed 2014-05-14 | $0.00 10-Q · filed 2014-05-14 | ||||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-13 | |||||
| 2013-06-30 | $0.00 10-K · filed 2014-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |